• Xeris Biopharma filed patent infringement suits on Oct. 13, 2026 in New Jersey federal court tied to KEVEYIS (dichlorphenamide).
• Actions follow issuance of U.S. Patent No. 12,758,502 covering the product.
• Claims target proposed generic dichlorphenamide products, alleging infringement through making, selling, or importing.
• Relief sought includes an injunction, monetary damages, enhanced damages, attorneys’ fees, and costs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001867096-26-000091), on October 14, 2026, and is solely responsible for the information contained therein.